Your browser doesn't support javascript.
loading
Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He, Miao; Wu, Huizhe; Jiang, Qian; Liu, Yinuo; Han, Li; Yan, Yuanyuan; Wei, Binbin; Liu, Fangxiao; Deng, Xiaolan; Chen, Huiying; Zhao, Lin; Wang, Min; Wu, Xin; Yao, Weifan; Zhao, Haishan; Chen, Jianjun; Wei, Minjie.
Afiliação
  • He M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Wu H; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Shenyang, China.
  • Jiang Q; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Liu Y; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Shenyang, China.
  • Han L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Yan Y; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Shenyang, China.
  • Wei B; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Liu F; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Shenyang, China.
  • Deng X; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Chen H; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Shenyang, China.
  • Zhao L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Wang M; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Shenyang, China.
  • Wu X; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Yao W; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Shenyang, China.
  • Zhao H; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
  • Chen J; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Shenyang, China.
  • Wei M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Mol Oncol ; 13(2): 403-421, 2019 02.
Article em En | MEDLINE | ID: mdl-30536571
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Células-Tronco Neoplásicas / Doxorrubicina / Resistencia a Medicamentos Antineoplásicos / Fatores de Transcrição Hélice-Alça-Hélice Básicos / Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Oncol Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Células-Tronco Neoplásicas / Doxorrubicina / Resistencia a Medicamentos Antineoplásicos / Fatores de Transcrição Hélice-Alça-Hélice Básicos / Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Mol Oncol Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China